Your browser doesn't support javascript.
loading
Inhibition of endocannabinoid degradation rectifies motivational and dopaminergic deficits in the Q175 mouse model of Huntington's disease.
Covey, Dan P; Dantrassy, Hannah M; Yohn, Samantha E; Castro, Alberto; Conn, P Jeffrey; Mateo, Yolanda; Cheer, Joseph F.
Afiliação
  • Covey DP; Department of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Dantrassy HM; Department of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Yohn SE; Department of Pharmacology, Vanderbilt Kennedy Center, Vanderbilt University School of Medicine, Nashville, TN, USA.
  • Castro A; Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, 37232, USA.
  • Conn PJ; Department of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Mateo Y; Department of Pharmacology, Vanderbilt Kennedy Center, Vanderbilt University School of Medicine, Nashville, TN, USA.
  • Cheer JF; Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, 37232, USA.
Neuropsychopharmacology ; 43(10): 2056-2063, 2018 09.
Article em En | MEDLINE | ID: mdl-29925886
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Dopamina / Doença de Huntington / Endocanabinoides / Motivação Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Dopamina / Doença de Huntington / Endocanabinoides / Motivação Idioma: En Ano de publicação: 2018 Tipo de documento: Article